Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy

Sex Transm Infect. 2020 Aug;96(5):337-341. doi: 10.1136/sextrans-2020-054439. Epub 2020 Apr 3.

Abstract

Objective: To provide insight on viral kinetics and genetic diversity of HIV in seminal plasma at baseline and 1 month after initiating antiretroviral therapy (ART).

Patients and methods: Blood and seminal samples from patients with newly diagnosed HIV were obtained before ART initiation (T0) and 1 month after ART initiation (T1). HIV env genetic diversity was studied using deep sequencing Nextera and V3 chemistry in a MiSeq Illumina platform. The number of viral quasispecies (5% cut-off) and Shannon Index were used to analyse diversity.

Results: Forty-seven ART-naive patients were recruited between September 2016 and November 2018. At enrolment, the number of quasispecies in blood (median 4 (IQR 2-5)) was lower than in the seminal compartment (median 6, (IQR 4-8)) (p<0.01); the Shannon Index was also higher (p<0.001) in the seminal compartment than in blood (1.77 vs 0.64). At T1, for the 13 patients with detectable HIV in both blood/seminal plasma, viral diversity remained higher (p=0.139) in seminal plasma (median 2 (IQR 1-4.5)) than in blood (median 1 (IQR 1-1.5)) Integrase inhibitors (INI)-based regimens achieved higher levels of undetectability and led more frequently to lower variability (p<0.001) than protease inhibitors (PI) or non-nucleoside reverse transcriptase inhibitors (NNRTI).

Conclusion: We provide here further evidence of a larger genetic diversity in seminal plasma, both at diagnosis and short term after ART initiation. Our results strengthen previous findings on HIV diversity in seminal plasma. In addition, INIs decrease variability more rapidly than PI and NNRTI in both blood and seminal plasma.

Keywords: DNA amplification; HIV; HIV therapeutics; antiretroviral therapy; virology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use*
  • Blood / virology*
  • Genetic Variation*
  • HIV / genetics*
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV Integrase Inhibitors / therapeutic use
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Male
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Semen / virology*
  • env Gene Products, Human Immunodeficiency Virus / genetics*

Substances

  • Anti-Retroviral Agents
  • HIV Integrase Inhibitors
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • env Gene Products, Human Immunodeficiency Virus